Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study

BACKGROUND: The CDK4/6 inhibitor palbociclib combined with endocrine therapy (ET) has proven to prolong progression-free survival (PFS) in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC). Few data are available regar...

Descripción completa

Detalles Bibliográficos
Autores principales: Palumbo, Raffaella, Torrisi, Rosalba, Sottotetti, Federico, Presti, Daniele, Rita Gambaro, Anna, Collovà, Elena, Ferzi, Antonella, Agostinetto, Elisa, Maria Teragni, Cristina, Saltalamacchia, Giuseppe, Tagliaferri, Barbara, Balletti, Emanuela, Bernardo, Antonio, Quaquarini, Erica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970542/
https://www.ncbi.nlm.nih.gov/pubmed/33796150
http://dx.doi.org/10.1177/1758835920987651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970542/
https://www.ncbi.nlm.nih.gov/pubmed/33796150
http://dx.doi.org/10.1177/1758835920987651

Ejemplares similares